Current Hepatitis Reports

, Volume 9, Issue 2, pp 53–59

Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment


DOI: 10.1007/s11901-010-0036-4

Cite this article as:
Vermehren, J., Kau, A. & Zeuzem, S. Curr Hepatitis Rep (2010) 9: 53. doi:10.1007/s11901-010-0036-4


Persistently high levels of hepatitis B virus (HBV) DNA in patients with chronic HBV infection have been clearly implicated in an increased risk of liver cirrhosis and hepatocellular carcinoma. Hence, the primary objective of antiviral treatment is profound and lasting suppression of HBV DNA levels to improve long-term patient outcomes. Analyses of various patient and treatment characteristics have identified baseline and on-treatment factors that may be helpful in achieving this goal. In this article, the available data on baseline and on-treatment predictors of treatment outcomes in patients with chronic hepatitis B treated with both (pegylated) interferon and nucleos(t)ide analogues are reviewed.


Hepatitis B Pegylated interferon Lamivudine Adefovir Telbivudine Entecavir Tenofovir Treatment predictors 

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität Frankfurt am MainFrankfurt am MainGermany

Personalised recommendations